Peter Socrates Creticos
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Peter Socrates Creticos has a total of 32 co-authors. Here are the top co-authors by number of shared publications:
- Anthony J. Frew
Department of Respiratory Medicine, Royal Sussex County Hospital, Brighton, UK
1 shared publication Antonella Muraro
Food Allergy Referral Centre, Padua University Hospital Padua, Italy
1 shared publication- Bettina Wedi
Department of Dermatology and Allergy, Comprehensive Allergy Center, Hannover Medical School, Hannover, Germany
1 shared publication - Carmen Vidal
Allergy Service Complejo Hospitalario Universitario de Santiago Santiago de Compostela Spain
1 shared publication Carsten Bindslev‐Jensen
Department of Dermatology and Allergy Centre, Odense University Hospital, Odense Research Center for Anaphylaxis (ORCA), Odense, Denmark
1 shared publication- Désirée Larenas-Linnemann
Centro de Excelencia en Asma y Alergia Larenas, Hospital Médica Sur, Mexico City, Mexico
1 shared publication
Latest Publications
- Open Access
Placebo effects in allergen immunotherapy—An EAACI Task Force Position Paper
The placebo (Latin “I will please”) effect commonly occurs in clinical trials. The psychological and physiological factors associated with patients’ expectations about a treatment's positive and negative effects have yet to be well characterized, although a functional prefrontal cortex and intense bidirectional communication between the central nervous system and the immune system appear to be prerequisites for a placebo effect. The use of placebo raises certain ethical issues, especially if patients in a placebo group are denied an effective treatment for a long period of time. The placebo effect appears to be relatively large (up to 77%, relative to pretreatment scores) in controlled clinical trials of allergen immunotherapy (AIT), such as the pivotal, double‐blind, placebo‐controlled (DBPC) randomized clinical trials currently required by regulatory authorities worldwide. The European Academy of Allergy and Clinical Immunology (EAACI) therefore initiated a Task Force, in order to better understand the placebo effect in AIT and its specific role in comorbidities, blinding issues, adherence, measurement time points, variability and the natural course of the disease. In this Position Paper, the EAACI Task Force highlights several important topics regarding the placebo effect in AIT such as a) regulatory aspects, b) neuroimmunological and psychological mechanisms, c) placebo effect sizes in AIT trials, d) methodological limitations in AIT trial design and e) potential solutions in future AIT trial design. In conclusion, this Position Paper aims to examine the methodological problem of placebo in AIT from different aspects and also to highlight unmet needs and possible solutions for future trials.
Open AccessPlacebo effects in allergen immunotherapy—An EAACI Task Force Position Paper
The placebo (Latin “I will please”) effect commonly occurs in clinical trials. The psychological and physiological factors associated with patients’ expectations about a treatment's positive and negative effects have yet to be well characterized, although a functional prefrontal cortex and intense bidirectional communication between the central nervous system and the immune system appear to be prerequisites for a placebo effect. The use of placebo raises certain ethical issues, especially if patients in a placebo group are denied an effective treatment for a long period of time. The placebo effect appears to be relatively large (up to 77%, relative to pretreatment scores) in controlled clinical trials of allergen immunotherapy (AIT), such as the pivotal, double‐blind, placebo‐controlled (DBPC) randomized clinical trials currently required by regulatory authorities worldwide. The European Academy of Allergy and Clinical Immunology (EAACI) therefore initiated a Task Force, in order to better understand the placebo effect in AIT and its specific role in comorbidities, blinding issues, adherence, measurement time points, variability and the natural course of the disease. In this Position Paper, the EAACI Task Force highlights several important topics regarding the placebo effect in AIT such as a) regulatory aspects, b) neuroimmunological and psychological mechanisms, c) placebo effect sizes in AIT trials, d) methodological limitations in AIT trial design and e) potential solutions in future AIT trial design. In conclusion, this Position Paper aims to examine the methodological problem of placebo in AIT from different aspects and also to highlight unmet needs and possible solutions for future trials.
- 1 April 2020
- Published by Elsevier in Annals of Allergy, Asthma & Immunology
- Vol. 124 (4) , 314-317
Acute emotional stress proposed as a risk factor for anaphylaxis in patients receiving allergen immunotherapy
- 1 April 2020
- Published by Elsevier in Annals of Allergy, Asthma & Immunology
- Vol. 124 (4) , 314-317
Acute emotional stress proposed as a risk factor for anaphylaxis in patients receiving allergen immunotherapy
- 1 January 1992
- Published by S. Karger AG in International Archives of Allergy and Immunology
- Vol. 99 (2-4) , 257-260
Immunotherapy of Allergic Disorders: Traditional and Novel Approaches
For approaches to the immunotherapy of allergic respiratory diseases now under study at Johns Hopkins are reviewed. Traditional high dose parenteral immunization with mixtures of allergens corresponding to patients’ allergic sensitivities is being evaluated in the long-term management of allergic asthma in children. Oral desensitization employing doses of short ragweed extract 100 fold higher than for parenteral therapy has been proven safe and efficacious and is now being modified to render it practicable. Intradermal injections of autologous IgG immune complexes with D. pteronyssinus antigens has been reported to improve symptoms and reduce IgE synthesis; a trial to replicate these findings is underway. Immunization with immunodominant peptides from Fel d. I is also under development as a novel immunoregulatory intervention with potential clinical application.
- 1 January 1992
- Published by S. Karger AG in International Archives of Allergy and Immunology
- Vol. 99 (2-4) , 257-260
Immunotherapy of Allergic Disorders: Traditional and Novel Approaches
For approaches to the immunotherapy of allergic respiratory diseases now under study at Johns Hopkins are reviewed. Traditional high dose parenteral immunization with mixtures of allergens corresponding to patients’ allergic sensitivities is being evaluated in the long-term management of allergic asthma in children. Oral desensitization employing doses of short ragweed extract 100 fold higher than for parenteral therapy has been proven safe and efficacious and is now being modified to render it practicable. Intradermal injections of autologous IgG immune complexes with D. pteronyssinus antigens has been reported to improve symptoms and reduce IgE synthesis; a trial to replicate these findings is underway. Immunization with immunodominant peptides from Fel d. I is also under development as a novel immunoregulatory intervention with potential clinical application.